PT-141 10mg Peptide

PT-141 is what Melanotan II becomes after loss of the C-terminal amide, and that single change shifts its selectivity away from MC1R pigmentation activity toward MC3R and MC4R. Because MC4R signalling in the hypothalamus is the pathway involved, its mechanism is central rather than peripheral, which distinguishes it categorically from PDE5 inhibitors. It reached regulatory approval as Vyleesi, giving it a far more complete safety and pharmacokinetic dataset than most compounds in this catalogue. Nausea through the same central pathway is the dose-limiting effect reported across that dataset.